TY  - BOOK
AU  - Breggin,Peter Roger
TI  - Brain-disabling treatments in psychiatry: drugs, electroshock, and the psychopharmaceutical complex 
SN  - 9780826129345 (alk. paper)
AV  - RC483 .B72 2008
U1  - 616.89/122 22
PY  - 2008///
CY  - New York
PB  - Springer Pub.
KW  - United States
KW  - Food and Drug Administration
KW  - Psychotropic drugs
KW  - Side effects
KW  - Brain
KW  - Effect of drugs on
KW  - Electroconvulsive therapy
KW  - Complications
KW  - Iatrogenic diseases
KW  - Mental Disorders
KW  - therapy
KW  - Brain Damage, Chronic
KW  - etiology
KW  - Drug Industry
KW  - Electroconvulsive Therapy
KW  - adverse effects
KW  - Psychotropic Drugs
N1  - Includes bibliographical references (p. 463-526) and index; The brain-disabling, spellbinding effects of psychiatric drugs -- Deactivation syndrome (chemical lobotomy) caused by neuroleptics -- neuroleptic-induced anguish, including agitation, despair, and depression -- Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics -- Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis -- Recent developments in antidepressant label changes -- Antidepressant-induced mental, behavioral, and cerebral abnormalities -- Lithium and other drugs for bipolar disorder -- Electroconvulsive therapy (ECT) for depression -- From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children -- Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions -- Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion -- The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates -- Drug company deceptions -- How to more safely stop taking psychiatric drugs -- Failed promises, last resorts, and psychotherapy
UR  - http://www.loc.gov/catdir/toc/ecip0723/2007029727.html
ER  -